Real-world data suggest that Erleada may offer an advantage over other treatment options for patients with metastatic ...

Most men who are treated for prostate cancer according to modern guidelines have good survival rates and the majority of these men will die of causes ...

Data from clinical trials have indicated that PSA is prognostic for outcomes, but little is known about real-world trends.

A new population-level study from Uppsala University has found that most men treated for non-metastatic prostate cancer according to current clinical guidelines have a favorable long-term prognosis.

During a live event, Jahan Aghalar, MD, discussed key NCCN-recommended oral therapies and landmark trials for metastatic ...

Journal of the National Comprehensive Cancer Network finds that for people diagnosed with nonmetastatic low-risk prostate ...

Charlottesville, Va.-based UVA Health is expanding its Stay in the Game initiative, a targeted prostate cancer screening program aimed at boosting early detection among Black men. Speaking with Becker ...

Pfizer and Astellas’ Xtandi (enzalutamide) has improved overall survival (OS) in patients with nmHSPC, but only as a combination therapy.

J&J has rights to niraparib in prostate cancer, and views the drug as a successor to Zytiga, once a $2.5 billion-a-year ...

Prostate cancer is the second most common cancer diagnosis in men. About one in eight men will be diagnosed with this disease during their lifetime. New Mexico Living spoke with Dr. Jose Avitia ...